Benitec Biopharma Price to Sales Ratio 2014-2023 | BNTC

Historical PS ratio values for Benitec Biopharma (BNTC) over the last 10 years. The current P/S ratio for Benitec Biopharma as of May 31, 2023 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Benitec Biopharma P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2023-05-31 0.24 98.90
2023-03-31 0.21 $0.00 0.00
2022-12-31 0.17 $0.01 0.00
2022-09-30 0.37 $0.01 0.00
2022-06-30 1.16 $0.01 0.00
2022-03-31 2.34 $0.01 0.00
2021-12-31 2.62 $0.00 0.00
2021-09-30 3.57 $0.00 0.00
2021-06-30 4.25 $0.05 84.08
2021-03-31 5.17 $-7.01 0.00
2020-12-31 3.00 $1.98 1.51
2020-09-30 6.28 $1.98 3.17
2020-06-30 7.91 $1.93 4.09
2016-09-30 14.00 $8.99 1.56
2016-06-30 12.68 $5.19 2.45
2016-03-31 17.10 $5.19 3.30
2015-12-31 40.20 $5.22 7.70
2020-03-31 3.93 $6.41 0.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.845B 8.18
GSK (GSK) United Kingdom $69.327B 9.67
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.313B 21.77
Ginkgo Bioworks Holdings (DNA) United States $3.608B 0.00
Arcus Biosciences (RCUS) United States $1.481B 0.00
Biohaven (BHVN) United States $1.111B 0.00
Emergent Biosolutions (EBS) United States $0.415B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.175B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00